Please select
your location below

Attenzione, le pagine di questa sezione sono disponibili solo in lingua inglese.

By selecting the International view, you verify that you reside outside of the USA and you wish to view DiaSorin Molecular’s International Product Information. This material is intended for International (non-USA) site visitors only.

Pursuant to the Guidelines of the Ministry of Health dated 28/03/2013 related to health advertising concerning medical devices, in vitro diagnostic medical devices and medical-surgical devices, we hereby inform you that the information contained in this website and to which you are going to access is exclusively intended for professionaloperators.

NxTAG^® Respiratory Pathogen Panel v2

Pre-plated, lyophilized reagents facilitate a simple workflow with just one pipetting step, ensuring an easy fit in any lab’s daily routine

Detect 19 viral pathogens, including SARS‑CoV‑2, and two bacterial pathogens in a single well, enabling thorough respiratory health analysis.

NxTAG<sup>®</sup> Respiratory Pathogen Panel V2

Disease state

Respiratory tract infections involve a wide variety of etiologic agents, and present with overlapping signs and symptoms. Prediction of the causative organism based on clinical findings alone is not reliable. The most frequent agents responsible for respiratory infections are respiratory viruses, and then bacteria. It is important to ensure accurate detection of causative agents, especially in high-risk individuals and/or critically ill patients. Reflexing from negative targeted tests to determine unknown causes in ongoing sick individuals is key for appropriate patient management and or isolation. Panel testing is also highly valuable in determining respiratory pathogen outbreaks outside winter seasons.¹

¹ The Global Impact of Respiratory Disease. Third Edition. Page 33. Internet. https://www.firsnet.org/images/publications/FIRS_Master_09202021.pdf

Acute respiratory infection (ARI) is a leading cause of morbidity and mortality worldwide¹

The value of NxTAG^®
Respiratory Pathogen Panel v2

Empower laboratories with a cost-effective, highly scalable syndromic respiratory panel

Clinical impact

Produce high-quality, trustworthy results for a broad spectrum of pathogens, including SARS-CoV-2. Face rising co-infections and fluctuating etiological agents with proven technology. Guide timely and appropriate treatment decisions for inpatients and high-risk patients.

Outstanding economic value

Cost effective reagents within a closed tube system reduce total workflow costs and minimize contamination.

Scalable format

A scored 96-well test plate allows you to run 1 to 94 samples to meet your sample volume and throughput needs.

How the NxTAG^® Respiratory Pathogen Panel v2 Test works

NxTAG^® Respiratory Pathogen Panel v2 is a multiplexed in-vitro diagnostic test for the detection and identification of respiratory disease-causing viruses and bacteria from extracted nucleic acid samples.

Add

Add 1-94 extracted samples to pre-plated test wells containing lypholized reagents.

Integrate

Integrated multiplex PCR and bead hybridization.

Read

Read on the NxTAG^®-Enabled MAGPIX^® System.

Indications for NxTAG^® Respiratory Pathogen Panel v2 use

Diagnostic

A qualitative test intended for the simultaneous detection and identification of nucleic acids from multiple respiratory viruses and bacteria extracted from upper respiratory tract specimens

Patients

Hospitalized, Emergency Room or outpatient individuals with clinical signs and symptoms of a respiratory tract infection

Use area

Hospital, Public Health or Reference testing laboratories skilled in high-complexity methods